The response to single disease modifying antirheumatic drug (DMARD) is often suboptimal in patients with rheumatoid arthritis (RA). Thus, despite the limited data on the therapeutic efficacy of combination therapies, many patients are currently treated with a combination of DMARDs.
References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.
The response to single disease modifying antirheumatic drug (DMARD) is often suboptimal in patients with rheumatoid arthritis (RA). Thus, despite the limited data on the therapeutic efficacy of combination therapies, many patients are currently treated with a combination of DMARDs.
Clinical and experimental rheumatology – Pubmed
Published: Jan 12, 2000
Access the full text.
Sign up today, get DeepDyve free for 14 days.